AU2011224241B2 - The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas - Google Patents

The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas Download PDF

Info

Publication number
AU2011224241B2
AU2011224241B2 AU2011224241A AU2011224241A AU2011224241B2 AU 2011224241 B2 AU2011224241 B2 AU 2011224241B2 AU 2011224241 A AU2011224241 A AU 2011224241A AU 2011224241 A AU2011224241 A AU 2011224241A AU 2011224241 B2 AU2011224241 B2 AU 2011224241B2
Authority
AU
Australia
Prior art keywords
fenoterol
methoxy
tumor
compound
ethylfenoterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2011224241A
Other languages
English (en)
Other versions
AU2011224241A1 (en
Inventor
Michel Bernier
Lucita Arenas Jimenez
Lawrence Robert Toll
Irving W. Wainer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SRI International Inc
US Department of Health and Human Services
Original Assignee
SRI International Inc
Stanford Research Institute
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SRI International Inc, Stanford Research Institute, Government of the United States of America filed Critical SRI International Inc
Publication of AU2011224241A1 publication Critical patent/AU2011224241A1/en
Assigned to THE UNITED STATES OF AMERICA, as representated by the Secretary, Department of Health and Human Services, SRI INTERNATIONAL reassignment THE UNITED STATES OF AMERICA, as representated by the Secretary, Department of Health and Human Services Amend patent request/document other than specification (104) Assignors: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES
Assigned to THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES, SRI INTERNATIONAL reassignment THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Amend patent request/document other than specification (104) Assignors: SRI INTERNATIONAL, THE UNITED STATES OF AMERICA, as representated by the Secretary, Department of Health and Human Services
Application granted granted Critical
Publication of AU2011224241B2 publication Critical patent/AU2011224241B2/en
Priority to AU2014210656A priority Critical patent/AU2014210656B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2011224241A 2010-03-10 2011-03-10 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas Active AU2011224241B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2014210656A AU2014210656B2 (en) 2010-03-10 2014-08-08 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31264210P 2010-03-10 2010-03-10
US61/312,642 2010-03-10
PCT/US2011/027988 WO2011112867A1 (en) 2010-03-10 2011-03-10 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2014210656A Division AU2014210656B2 (en) 2010-03-10 2014-08-08 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Publications (2)

Publication Number Publication Date
AU2011224241A1 AU2011224241A1 (en) 2012-09-20
AU2011224241B2 true AU2011224241B2 (en) 2014-05-08

Family

ID=43858307

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011224241A Active AU2011224241B2 (en) 2010-03-10 2011-03-10 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
AU2014210656A Active AU2014210656B2 (en) 2010-03-10 2014-08-08 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2014210656A Active AU2014210656B2 (en) 2010-03-10 2014-08-08 The use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas

Country Status (7)

Country Link
US (4) US9492405B2 (enExample)
EP (1) EP2544676B1 (enExample)
JP (1) JP5837890B2 (enExample)
AU (2) AU2011224241B2 (enExample)
BR (1) BR112012022552A8 (enExample)
CA (1) CA2791702C (enExample)
WO (1) WO2011112867A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2854855B1 (en) 2012-05-25 2016-04-27 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of regulating cannabinoid receptor activity-related disorders and diseases
EP3125878A4 (en) * 2014-04-03 2017-11-29 Mitchell Woods Pharmaceuticals, Inc. Methods of treating breast cancer
WO2015153725A2 (en) * 2014-04-03 2015-10-08 Mitchell Woods Pharmaceuticals, Inc. Methods of treating melanoma
KR101585619B1 (ko) * 2014-11-20 2016-01-15 주식회사 아모텍 감전보호소자 및 이를 구비한 휴대용 전자장치
US20180042867A1 (en) * 2015-03-06 2018-02-15 Mitchell Woods Pharmaceuticals, Inc. Methods of treating cancer
WO2017059268A1 (en) * 2015-10-01 2017-04-06 Mitchell Woods Pharmaceuticals, Inc. Methods of reducing chemoresistance and treating cancer
EP3371181A4 (en) * 2015-10-18 2019-10-16 Onco Therapies LLC COMPOSITIONS AND METHODS FOR REGULATING DISORDERS AND DISEASES ASSOCIATED WITH CANCER
US20190240293A1 (en) * 2016-07-26 2019-08-08 Flagship Pioneering Innovations V, Inc. Neuromodulating compositions and related therapeutic methods for the treatment of cancer by modulating an anti-cancer immune response
GB201714740D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714745D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714736D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
GB201714734D0 (en) 2017-09-13 2017-10-25 Atrogi Ab New compounds and uses
CN109942462B (zh) * 2019-03-06 2022-01-14 宏冠生物药业有限公司 一种盐酸班布特罗的合成工艺
GB201903832D0 (en) 2019-03-20 2019-05-01 Atrogi Ab New compounds and methods
CN114456078B (zh) * 2022-01-19 2022-09-16 汉瑞药业(荆门)有限公司 一种(r)-n-苄基-1-(4-甲氧基苯基)丙-2-胺的制备方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022038A1 (en) * 2006-08-10 2008-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
WO2008075104A1 (en) * 2006-12-19 2008-06-26 University Of Leicester Modulators of beta-2-adrenergic receptor for treating conditions characterized by disorganized vasculature

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL296701A (enExample)
SE354279B (enExample) 1969-06-13 1973-03-05 Draco Ab
DE1962497C3 (de) 1969-12-12 1979-09-20 C.H. Boehringer Sohn, 6507 Ingelheim Naphthylalkyl- a -hydroxyphenäthyl-amine, ihre Herstellung und diese enthaltende Arzneimittel
CH556323A (de) 1969-12-12 1974-11-29 Boehringer Sohn Ingelheim Verfahren zur herstellung von neuen naphthylalkylaminen.
DE2010883A1 (de) 1970-03-07 1971-09-23 Troponwerke Dinklage & Co, 5000 Köln-Mülheim Pharmakologisch wirksame Aminoalkohole und Verfahren zu ihrer Darstellung
AT308139B (de) 1970-07-27 1973-06-25 Degussa Verfahren zur Herstellung von neuen basisch substituierten Alkyltheophyllinen, ihren Isomeren und Säureadditionssalzen
IT1044214B (it) 1971-04-22 1980-03-20 Zambeletti Spa L 2 idrossi 2 feniletilamine so stituite dotate di proprieta vasoattive e processo per la loro preparazione
JPS532194B2 (enExample) 1973-08-10 1978-01-26
US5795564A (en) 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
GB9107196D0 (en) 1991-04-05 1991-05-22 Sandoz Ag Improvements in or relating to organic compounds
US6299863B1 (en) 1992-04-03 2001-10-09 Sepracor Inc. Aerosol formulations containing micronized optically pure (R,R) formoterol for bronchodilating therapy
US6866839B2 (en) 1991-04-05 2005-03-15 Sepracor Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
DE69325454T2 (de) 1992-04-17 2000-01-20 Abbott Laboratories, Abbott Park Taxol-derivate
AU4408897A (en) 1996-07-05 1998-02-02 E.C. Pesterfield Associates, Inc. Method of treating retinal ischemia and glaucoma, using optically pure r- or rr- isomers of adrenergic beta-2 agonists
US6015837A (en) 1996-08-29 2000-01-18 New York Medical College Method for treating scoliosis with β2-adrenoceptor agonists
US5912264A (en) 1997-03-03 1999-06-15 Bristol-Myers Squibb Company 6-halo-or nitrate-substituted paclitaxels
WO1999016430A1 (en) 1997-09-30 1999-04-08 E.C. Pesterfield Associates, Inc. Galenic forms of r-or rr-isomers of adrenergic beta-2 agonists
ZA994264B (en) 1998-07-01 2000-01-25 Warner Lambert Co Stereoisomers with high affinity for adrenergic receptors.
AU6167599A (en) 1998-09-30 2000-04-17 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Use of a beta2 adrenergic receptor agonist in the treatment of cardiovascular disease
CO5280224A1 (es) 2000-02-02 2003-05-30 Univ Florida State Res Found Taxanos sustituidos con ester en c7, utiles como agentes antitumorales y composiciones farmaceuticas que los contienen
EP1370521B1 (en) 2001-03-22 2007-12-19 Glaxo Group Limited Formanilide derivatives as beta2-adrenoreceptor agonists
JP2005527618A (ja) 2002-05-28 2005-09-15 セラヴァンス インコーポレーテッド アルコキシアリールβ２アドレナリン作動性レセプターアゴニスト
CA2496477C (en) 2002-08-23 2012-10-16 Sloan-Kettering Institute For Cancer Research Synthesis of epothilones, intermediates thereto, analogues and uses thereof
US20050107417A1 (en) 2003-07-28 2005-05-19 Boehringer Ingelheim International Gmbh Medicaments for inhalation comprising a novel anticholinergic and a betamimetic
CA2544763A1 (en) 2003-11-03 2005-05-12 Myogen, Inc. 1,4-dihydropyridine compounds, pharmaceutical compositions, and methods for the treatment of cardiovascular disease
CA2560538A1 (en) 2004-03-22 2005-10-06 Myogen, Inc. (r)-enoximone sulfoxide and its use in the treatment of pde-iii mediated diseases
WO2006015830A1 (en) 2004-08-09 2006-02-16 Universite Catholique De Louvain Use of agonists and antagonists of beta-adrenoceptors for treating arterial diseases
CN101137625A (zh) 2005-01-11 2008-03-05 葛兰素集团有限公司 β2肾上腺素能激动剂的肉桂酸盐
US9381166B2 (en) 2007-10-02 2016-07-05 Rigshospitalet Systemic pro-hemostatic effect of sympathicomimetics with agonistic effects on alfa-adrenergic and/or beta-adrenergic receptors of the sympathetic nervous system, related to improved clot strength
US9295651B2 (en) * 2009-12-23 2016-03-29 The Board Of Trustees Of The University Of Illinois Nanoconjugates and nanoconjugate formulations

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008022038A1 (en) * 2006-08-10 2008-02-21 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Preparation of (r,r)-fenoterol and (r,r)- or (r,s)-fenoterol analogues and their use in treating congestive heart failure
WO2008075104A1 (en) * 2006-12-19 2008-06-26 University Of Leicester Modulators of beta-2-adrenergic receptor for treating conditions characterized by disorganized vasculature

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Carie A.E. et al. "A chemical biology approach identifies a beta-2 adrenergic receptor agonist that causes human tumor regression by blocking the Raf-1/Mek-1/Erk1/2 pathway", ONCOGENE (2007) Vol. 26, No. 26, pages 3777-3788 *
Kinnard, Roger L. et al. "Sympathetic Nervous System and Glioma Growth" EUROPEAN JOURNAL OF CANCER AND CLINICAL ONCOLOGY (1986) Vol. 22 No. 4 pages 501-503 *

Also Published As

Publication number Publication date
JP5837890B2 (ja) 2015-12-24
WO2011112867A8 (en) 2012-09-27
EP2544676B1 (en) 2018-09-19
US10130594B2 (en) 2018-11-20
US10617654B2 (en) 2020-04-14
US20190008802A1 (en) 2019-01-10
US10925840B2 (en) 2021-02-23
BR112012022552A2 (pt) 2016-08-30
EP2544676A1 (en) 2013-01-16
AU2014210656A1 (en) 2014-08-28
US20200197332A1 (en) 2020-06-25
CA2791702C (en) 2018-05-29
US20170007556A1 (en) 2017-01-12
US20130005799A1 (en) 2013-01-03
WO2011112867A1 (en) 2011-09-15
CA2791702A1 (en) 2011-09-15
JP2013522230A (ja) 2013-06-13
BR112012022552A8 (pt) 2017-12-05
AU2014210656B2 (en) 2016-03-17
US9492405B2 (en) 2016-11-15
AU2011224241A1 (en) 2012-09-20

Similar Documents

Publication Publication Date Title
US10925840B2 (en) Use of fenoterol and fenoterol analogues in the treatment of glioblastomas and astrocytomas
US10562843B2 (en) Preparation of (R,R)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure
US20180042867A1 (en) Methods of treating cancer
AU2013202127B2 (en) Preparation of (R,R-)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure
US20170172945A1 (en) Methods of treating breast cancer
AU2014224073A1 (en) Preparation of (R,R-)-fenoterol and (R,R)- or (R,S)-fenoterol analogues and their use in treating congestive heart failure
WO2018140923A1 (en) Methods of treating cancer

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)